Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9350616 | 0.86 | TSHR (0.31) | TSHRMAPK1ATMTDP1L3MBTL1 | |
| SCHEMBL12626453 | 0.82 | CXCR1 (0.30) | — | |
| SCHEMBL13369341 | 0.82 | CXCR1 (0.30) | — | |
| SCHEMBL8228668 | 0.79 | GABRA1 (0.35) | TSHR | |
| SCHEMBL8224187 | 0.79 | — | — | |
| SCHEMBL24091389 | 0.79 | HTR1B (0.30) | — | |
| SCHEMBL13407030 | 0.79 | — | — | |
| SCHEMBL12260243 | 0.79 | — | — | |
| SCHEMBL13226811 | 0.79 | — | — | |
| SCHEMBL12626860 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-23 | — | — | US | disclosed |
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | CYP1A2 3491/4885NPC1 3130/4885ALDH1A1 3954/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | CYP1A2 1291/4885NPC1 1084/4885ALDH1A1 2279/4885 |
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | CYP1A2 4467/4885NPC1 3230/4885ALDH1A1 4468/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CYP1A2 763/4885NPC1 2374/4885ALDH1A1 1806/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | CYP1A2 804/4885NPC1 2398/4885ALDH1A1 1907/4885 |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | CYP1A2 2232/4885NPC1 760/4885ALDH1A1 1629/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CYP1A2 763/4885NPC1 2374/4885ALDH1A1 1806/4885 |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | CYP1A2 3187/4885NPC1 959/4885ALDH1A1 1717/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | CYP1A2 250/4885NPC1 219/4885ALDH1A1 2777/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP1A2 763/4885NPC1 2374/4885ALDH1A1 1806/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | CYP1A2 3187/4885NPC1 959/4885ALDH1A1 1717/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | CYP1A2 311/4885NPC1 2401/4885ALDH1A1 1908/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | CYP1A2 212/4885NPC1 1618/4885ALDH1A1 280/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP1A2 763/4885NPC1 2374/4885ALDH1A1 1806/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | CYP1A2 850/4885NPC1 2548/4885ALDH1A1 1875/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | CYP1A2 311/4885NPC1 2401/4885ALDH1A1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.